Avadel Pharmaceuticals Faces Activist Pressure Over Governance and Strategy
ASL Strategic Value Calls for Complete Board Replacement
Avadel Pharmaceuticals (AVDL) is confronting mounting pressure from activist investor ASL Strategic Value, which has formally urged shareholders to vote out the entire board at the upcoming annual meeting scheduled for late July.
- ASL, holding approximately $15 million in Avadel shares, alleges significant governance failures and poor strategic oversight.
- Year-to-date, Avadel’s stock has declined over 12%, reflecting investor concerns amid this ongoing boardroom battle.
Concerns Over Lumryz Launch and Missed Revenue
ASL highlights mismanagement in the launch of Avadel’s key drug, Lumryz, which is the first FDA-approved treatment for cataplexy and excessive daytime sleepiness (EDS) in adults with narcolepsy.
- The activist claims that poor execution has caused Avadel to forgo hundreds of millions of dollars in potential revenue.
- Avadel projects $255–265 million in net product revenue for Lumryz in 2025, based on an expected patient pool of 3,400 to 3,600.
Calls for Additional Corporate Actions
Beyond pushing for a new board, ASL urges Avadel to issue contingent-value rights to shareholders, granting them potential payouts tied to legal proceedings, including a case where Avadel seeks over $1 billion in damages.
- The activist also recommends hiring an investment bank to explore strategic alternatives, including a possible sale of the company.
- ASL made a similar call in February, which temporarily boosted Avadel’s stock price.
Avadel’s Response and Market Outlook
A company spokesperson affirmed the board’s active engagement with shareholders and noted directors’ personal investments in Avadel.
- The company remains focused on maximizing Lumryz’s value and delivering long-term shareholder returns.
- Despite current challenges, AVDL stock carries a Strong Buy consensus from analysts.
